Johnson & Johnson (NYSE:JNJ) finished Thursday with an addition of $2.9 to close at $166.18, an upside of 1.78 percent. An average of 10,039,580 shares of common stock have been traded in the last five days. There was a gain of $1.10 in the past week, and it reached a new high 24 times over the past 12 months. The last 20 days have seen an average of 7,446,695 shares traded, while the 50-day average volume stands at 6,976,080.
JNJ stock has increased by 0.03% in the last month. The company shares reached their 1-month lowest point of $160.81 on 09/13/22. With the stock rallying to its 52-week high on 04/25/22, shares of the company touched a low of $155.72 and a high of $186.69 in 52 weeks. It has reached a new high 19 times so far this year and lost -2.86% or -$4.89 in price. In spite of this, the price is down -10.99% from the 52-week high.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now.
105 days have passed since Johnson & Johnson (JNJ) last reported insider trading activity. Wengel Kathryn E, who is EVP, Chief GSC Officer, most recently acquired $40,000 shares at $173.00 per share on Jun 10. In this transaction, the insider spent $6,920,040. Controller, CAO, Decker Robert J, disposed of 8,462 shares at a price of $180.00 on May 26. The insider now owns more than $1,523,160 worth of shares. Prior to that, Hait William went on to Sale 29,699 shares at $183.58 each on Apr 21. An amount of $5,452,053 was transacted.
Johnson & Johnson (JNJ) has a trailing price-to-earnings (P/E) ratio of 24.16. The stock’s beta is 0.60. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 4.50, the price-to-book (PB) ratio at 5.72, and the price-to-cash flow ratio at 49.98.
The company has a payout ratio of 61.70%. The company’s most recent quarterly dividend payment was $1.13 a share, without any change from last year. Its latest increase dividend $0.07 reported on Tuesday April 19 2022.
The quick ratio of Johnson & Johnson for the three months ended June 29 was 1.20, and the current ratio was 1.40, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.37 and a total debt to equity ratio of 0.43 for the quarter ending June 29. Its gross profit as reported stood at $63.92 billion compared to revenue of $93.78 billion.
For the three-month period that ended June 29, Johnson & Johnson had $21.59 billion in cash and short-term investments compared to $28.29 billion in total debt. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of $4.81 billion in the quarter, while revenues of $5.15 billion were shrunk -30.41%. The analyst consensus anticipated Johnson & Johnson’s latest quarter earnings to come in at $2.53 per share, but it turned out to be $2.59, a 2.40% surprise. For the quarter, EBITDA amounted to $7.69 billion. Shareholders own equity worth $2.63 billion.
From a technical analysis perspective, let’s take a brief look at Johnson & Johnson (JNJ) price momentum. RSI 9-day as of the close on 22 September was 53.42%, suggesting the stock is Neutral, with historical volatility in this time frame at 23.28%.
As of today, JNJ’s price is $165.66 +0.67% or $1.10 from its 5-day moving average. JNJ is currently trading +0.36% higher than its 20-day SMA and -7.91% lower than its 100-day SMA. However, the stock’s current price level is -5.28% below the SMA50 and +1.99% above the SMA200.
The stochastic %K and %D were 58.65% and 66.01%, respectively, and the average true range (ATR) was 3.02. With the 14-day stochastic at 78.74% and the average true range at 2.91, the RSI (14) stands at 50.59%. The stock has reached -0.19 on the 9-day MACD Oscillator while the 14-day reading was at 0.09.
Daiwa Securities launched coverage on Johnson & Johnson (NYSE: JNJ) in its analyst report released on June 22, 2022. The firm assigned the stock an Outperform rating. The consensus rating for Johnson & Johnson (JNJ) among analysts is Overweight. According to current brokerage recommendations, 0 brokerage firms advise that investors sell JNJ, while 12 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 3 analysts, while 6 others rate it as a “buy”.